Validations Queue
47,884 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 3 of 23, 100 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
47,884
Reviewed
13
Filtered
2,297
page 3 / 23
Showing on page
100
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.64 | FDA ANDA218488: EVEROLIMUS (EVEROLIMUS) — APOTEX | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA018569: FUROSEMIDE (FUROSEMIDE) — EPIC PHARMA LLC | fda 2026-06-02 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA211535: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — CIPLA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA219593: PREGABALIN (PREGABALIN) — UNICHEM | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA212963: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — EUGIA PHARMA | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA214376: MYCOPHENOLATE SODIUM (MYCOPHENOLATE SODIUM) — YICHANG HUMANWELL | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA213603: GABAPENTIN (GABAPENTIN) — ZHEJIANG YONGTAI | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA201446: FALLBACK SOLO (LEVONORGESTREL) — LUPIN | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA021343: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA021379: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA204741: CAPECITABINE (CAPECITABINE) — AMNEAL PHARMS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA079204: LAMOTRIGINE (LAMOTRIGINE) — TARO | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA214275: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA217552: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ALEMBIC | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA213165: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA BLA125504: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA211482: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — AJANTA PHARMA LTD | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA125554: OPDIVO (NIVOLUMAB) — BRISTOL MYERS SQUIBB | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA209125: ZOLEDRONIC ACID (ZOLEDRONIC ACID) — EUGIA PHARMA | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA213362: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — DAITO | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA125166: SOLIRIS (ECULIZUMAB) — ALEXION PHARM | fda 2026-06-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA021366: CRESTOR (ROSUVASTATIN CALCIUM) — ASTRAZENECA | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA125261: STELARA (USTEKINUMAB) — CENTOCOR ORTHO BIOTECH INC | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA213912: LENALIDOMIDE (LENALIDOMIDE) — MYLAN | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA021731: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA210689: FOSAPREPITANT DIMEGLUMINE (FOSAPREPITANT DIMEGLUMINE) — LUPIN | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA078480: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — APOTEX | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA217186: CREXONT (CARBIDOPA) — IMPAX | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA219072: CARBAMAZEPINE (CARBAMAZEPINE) — YICHANG HUMANWELL | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA216992: DEFLAZACORT (DEFLAZACORT) — UPSHER SMITH LABS | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA218872: LENALIDOMIDE (LENALIDOMIDE) — ACCORD HLTHCARE | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA202667: COSOPT PF (DORZOLAMIDE HYDROCHLORIDE) — THEA PHARMA | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA072734: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA205422: REXULTI (BREXPIPRAZOLE) — OTSUKA | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA215276: NICOTINE POLACRILEX (NICOTINE POLACRILEX) — DR REDDYS LABS SA | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA208573: VENCLEXTA (VENETOCLAX) — ABBVIE | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA040054: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — HIKMA | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA219319: GABAPENTIN (GABAPENTIN) — SENORES PHARMS | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA081235: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — MYLAN | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA218405: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — MANKIND PHARMA LTD | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA220442: NDA220442 ((unspecified)) — SHIONOGI INC | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA210249: POMALIDOMIDE (POMALIDOMIDE) — EUGIA PHARMA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA210655: PERSERIS KIT (RISPERIDONE) — INDIVIOR | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA214957: GABAPENTIN (GABAPENTIN) — ASCENT PHARMS INC | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA220660: ELTROMBOPAG OLAMINE (ELTROMBOPAG OLAMINE) — AIZANT | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA215430: AUVELITY (BUPROPION HYDROCHLORIDE) — AXSOME | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA019010: LUPRON (LEUPROLIDE ACETATE) — ABBVIE ENDOCRINE INC | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA076958: LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) — TEVA | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA220717: ZOLPIDEM TARTRATE (ZOLPIDEM TARTRATE) — UMEDICA LABS PVT | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA212576: INQOVI (CEDAZURIDINE) — TAIHO ONCOLOGY | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA213093: ANDA213093 ((unspecified)) — QILU PHARM CO LTD | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA BLA761235: VABYSMO (FARICIMAB-SVOA) — GENENTECH INC | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA205756: METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE) — RISING | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA020785: THALOMID (THALIDOMIDE) — BRISTOL-MYERS | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA210236: POMALIDOMIDE (POMALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA BLA761034: TECENTRIQ (ATEZOLIZUMAB) — GENENTECH INC | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA212371: EMPAGLIFLOZIN (EMPAGLIFLOZIN) — AUROBINDO PHARMA LIMITED | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA220366: LACOSAMIDE (LACOSAMIDE) — STERANCO HLTHCARE | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA207717: OXCARBAZEPINE (OXCARBAZEPINE) — RUBICON RESEARCH | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA209091: QTERN (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA211022: LENALIDOMIDE (LENALIDOMIDE) — APOTEX | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA BLA125409: PERJETA (PERTUZUMAB) — GENENTECH | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA206863: DALFAMPRIDINE (DALFAMPRIDINE) — ACCORD HLTHCARE | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA761068: CRYSVITA (BUROSUMAB-TWZA) — KYOWA KIRIN | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA219473: CENOBAMATE (CENOBAMATE) — AUROBINDO PHARMA LIMITED | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA020515: ZOLADEX (GOSERELIN) — TERSERA | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA210308: YONSA (ABIRATERONE ACETATE) — SUN PHARM | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA210040: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — AMNEAL PHARMS | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA201749: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — SUN PHARM | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA022180: FERAHEME (FERUMOXYTOL) — AZURITY | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA079099: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA206252: QUETIAPINE FUMARATE (QUETIAPINE FUMARATE) — ACCORD HLTHCARE | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA220147: TOLVAPTAN (TOLVAPTAN) — ALKEM LABS LTD | fda 2026-04-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA210154: LENALIDOMIDE (LENALIDOMIDE) — ZYDUS PHARMS | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA220078: VORICONAZOLE (VORICONAZOLE) — ZHEJIANG NOVUS | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA208283: EPLERENONE (EPLERENONE) — BRECKENRIDGE | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA217379: NDA217379 ((unspecified)) — FLEX PHARMA, LLC | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA215332: OXCARBAZEPINE (OXCARBAZEPINE) — AUCTA | fda 2026-06-02 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA072735: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA079204: LAMOTRIGINE (LAMOTRIGINE) — TARO | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA204114: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — NOVARTIS | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA208433: LINAGLIPTIN (LINAGLIPTIN) — TEVA PHARMS USA | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA220482: NDA220482 ((unspecified)) — HAISCO PHARMACEUTICAL GROUP CO LTD | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA NDA201848: HEPZATO (MELPHALAN HYDROCHLORIDE) — DELCATH SYSTEMS INC | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.63 | FDA ANDA090170: LAMOTRIGINE (LAMOTRIGINE) — UNICHEM LABS LTD | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.63 | FDA ANDA218509: IVERMECTIN (IVERMECTIN) — AJANTA PHARMA LTD | fda 2026-04-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.63 | FDA ANDA200217: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% |